Acepodia partners with Pfizer Ignite to expand ACC therapies for autoimmune diseases.
Acepodia, a clinical-stage biotechnology firm, has partnered with Pfizer Ignite to enhance its Antibody-Cell Conjugation (ACC) therapies for autoimmune diseases. This collaboration will provide Acepodia with strategic support and resources, enabling it to expand its applications beyond cancer treatments.
7 months ago
5 Articles
You have 9 free stories remaining this month. Subscribe anytime for unlimited access.